Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hAESCs for Prevention of aGVHD After HSCT
NCT06444022Phase 1Withdrawn
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jun 2026
- Primary completion
- Dec 2027
01
Overview
Phase 1, randomised trial in Acute Graft-Versus-Host Disease (aGvHD) comparing hAESCs with Placebo (2 arms). Primary endpoint: Adverse Events and Serious Adverse Events at 1 year. Planned start Jun 2026; status: withdrawn.
02
Drugs
human amniotic epithelial stem cells
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT06444022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06444022.